Telmisartan inhibits AGE-induced podocyte damage and detachment
Telmisartan inhibits AGE-induced podocyte damage and detachment
复制标题
DOI:
10.1016/j.mvr.2013.04.006
复制
发表时间:
2013-07-01
影响因子:
3.1
通讯作者:
Okuda, Seiya
中科院分区:
文献类型:
--
作者:
Fukami, Kei;Yamagishi, Sho-ichi;Okuda, Seiya
Advanced glycation end products (AGE) formed at an accelerated rate under diabetes, could cause podocyte apoptosis, thereby being involved in the development and progression of diabetic nephropathy. Renin-angiotensin system (RAS) plays a role in diabetic nephropathy as well. However, it remains unknown whether there exists a pathophysiological crosstalk between the RAS and AGE in podocyte damage in diabetic nephropathy. Therefore, this study investigated the effects of telmisartan, an angiotensin II (Ang II) type 1 receptor (AT(1)R) blocker on AGE or Ang II-induced podocyte damage in vitro. We further examined here the effects of AGE on AT(1)R expression levels in podocytes. AGE or Ang II not only increased DNA damage of podocytes which was evaluated by comet assay, but also induced cell detachment, both of which were significantly blocked by the treatment with telmisartan. AGE significantly increased AT(1)R levels in podocytes, whereas podocyte Ang II production was modestly stimulated by AGE. Telmisartan alone did not affect the release of lactate dehydrogenase from podocytes. Our present study suggests that AGE could induce podocyte DNA damage and detachment partly via stimulation of the Ang II-AT(1)R axis, thus providing a novel beneficial aspect of telmisartan in diabetic nephropathy. (C) 2013 Elsevier Inc. All rights reserved.